BMBF; DZIF TTU-TB 02.705 Infrastructure „Myco Drug and Trials“
BMBF; DZIF TTU-TB 02.806 Project „New Drugs and Regimen“
BMBF; DZIF TTU-TB 02.906 FlexFund „Optimization of mycobacterial thioredoxin reductase inhibitors, novel lead compounds against M. tuberculosis“
BMBF; DZIF TTU-TI 07.003_Garrelts MD Project „Local activity of anti-TB therapeutics in highly stratified human-like lesions of a novel pre-clincial mouse model“
BMBF, DZIF „InhibitMycoRex: Optimization of mycobacterial thioredoxin reductase inhibitors, novel lead compounds against M. tuberculosis“
DFG; IRTG191: "Immunoregulation of Inflammation in Allergy and Infection“: Project B6 "ProThe impact of Tr1 cells in aged mice on susceptibility and vaccination efficacy in TB“
DFG; IRTG191: "Immunoregulation of Inflammation in Allergy and Infection“: MD Project "Spatial analysis of host and pathogen responses in highly structured tuberculous granulomas after laser capture microdissection“
DFG; GRK 1727: „Modulation von Autoimmunität“ : Projekt A3: "Cell type-specific effects of interleukin-17 in Epidermolysis bullous acquisita"
EU / Horizon 2020: CORVOS / Marie Sklodowska-Curie Joint European PhD:“ Complement regulation and variations in opportunistic infections“
EU / Horizon 2020: ETBRA / „European tuberculosis regimen accelerator“
Projects